Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Verastem ( (VSTM) ) has shared an announcement.
On February 4, 2026, Verastem Oncology reported preliminary, unaudited 2025 financial and clinical results, highlighting an estimated $17.5 million in fourth-quarter 2025 net product revenue and $30.9 million for full-year 2025 from its newly launched AVMAPKI FAKZYNJA CO-PACK, which received U.S. FDA approval in May 2025. The company ended 2025 with $205 million in cash, cash equivalents, and investments, or $234 million on a pro forma basis after the January 25, 2026 exercise of all remaining cash warrants that added $29.4 million, and it now expects its cash runway to extend into the first half of 2027 while anticipating that its low-grade serous ovarian cancer commercial franchise will become self-sustaining by the second half of 2026. Operationally, Verastem outlined 2026 priorities centered on maximizing U.S. uptake and pursuing geographic expansion of AVMAPKI FAKZYNJA CO-PACK, progressing confirmatory and label-expansion trials in LGSOC, and advancing its RAS/MAPK-focused pipeline, including an actively enrolling global Phase 1/2 program for VS-7375 in KRAS G12D solid tumors and combination studies in pancreatic and lung cancer. Updated clinical data from Japan’s RAMP201J trial showed encouraging response and disease control rates in both KRAS-mutated and KRAS wild-type recurrent LGSOC, and prior data from the RAMP 205 study in front-line metastatic pancreatic cancer showed an 83% overall response rate in the initial 12-patient cohort, positioning Verastem as a growing commercial-stage oncology player with multiple near- and mid-term clinical catalysts that could strengthen its competitive standing in targeted cancer therapeutics.
The most recent analyst rating on (VSTM) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Verastem stock, see the VSTM Stock Forecast page.
Spark’s Take on VSTM Stock
According to Spark, TipRanks’ AI Analyst, VSTM is a Neutral.
The score is held down primarily by weak financial performance (large ongoing losses, heavy cash burn, and negative equity with higher debt). Technicals also reflect recent downside momentum (below key moving averages and negative MACD). These are partly offset by a positive earnings-call outlook driven by strong initial commercial launch metrics, pipeline progress, and cash runway into 2H 2026.
To see Spark’s full report on VSTM stock, click here.
More about Verastem
Verastem Oncology (Nasdaq: VSTM) is a Boston-based biopharmaceutical company focused on developing and commercializing targeted therapies for RAS/MAPK pathway-driven cancers. Its lead commercial product is the AVMAPKI FAKZYNJA CO-PACK (avutometinib plus defactinib), the first U.S. FDA-approved treatment for adults with KRAS-mutated recurrent low-grade serous ovarian cancer, and it is advancing a pipeline that includes the investigational KRAS G12D inhibitor VS-7375 and combination regimens in solid tumors such as pancreatic, colorectal, and non-small cell lung cancers.
Average Trading Volume: 2,000,869
Technical Sentiment Signal: Sell
Current Market Cap: $470.7M
Find detailed analytics on VSTM stock on TipRanks’ Stock Analysis page.